Emily James

Emily is an Analyst with the Life Sciences team.

Emily recently finished her PhD in Pathology at the University of Cambridge, where her research focused on using multi-omics approaches to study cancers of the immune system.

Emily holds an MBiolSci in Biochemistry and Microbiology from the University of Sheffield and completed her master’s research at AstraZeneca in the Oncology Bioscience team.